Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breo

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

- PMLiVE

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will improve clinical trial engagement

- PMLiVE

Teva hit with largest-ever fine under US anti-corruption act

Company to pay $519m after promoting Copaxone in Russia, Ukraine and Mexico

- PMLiVE

Teva Generics Europe appoints president and CEO

Promotes former UK general manager Richard Daniell

- PMLiVE

NICE changes stance on GSK’s asthma drug Nucala

A newly-agreed price cut and additional cost-effectiveness data prompt U-turn

- PMLiVE

GSK files shingles vaccine Shingrix in Europe

Blockbuster hopeful would compete with Merck & Co’s Zostavax

- PMLiVE

Efficacy trials get underway for HIV vaccine in South Africa

Study hopes to provide partial immunity against the virus

- PMLiVE

GSK files first application for triple COPD therapy

Submits combo in the US one year early to coincide with EU marketing application

dengue fever mosquito

Dosing of GSK’s malaria vaccine due to start in 2018

WHO sanctions pilot programme in sub-Saharan Africa to begin gathering field data

- PMLiVE

GSK tops Access to Medicines Index for fifth time running

Leads J&J and Novartis in 'needs-orientation' while Roche and Astellas lag

- PMLiVE

Merck’s pharma unit faces tougher 2017 as fertility boost recedes

Looks to new products to drive growth as fertility drug rivals return to market

Back to the future

GSK’s choice of CEO is telling

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links